EBV mRNA Vaccine for HIV-Related Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests an experimental vaccine designed to train your immune system to fight EBV (Epstein-Barr virus), a virus that can contribute to certain lymphomas in people with HIV. You would receive this vaccine as an add-on treatment if standard chemotherapy hasn't fully controlled your lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have HIV-associated lymphoma (such as DLBCL, Burkitt, or Hodgkin lymphoma) confirmed by biopsy
- Your lymphoma tests positive for EBV virus (checked in tissue samples)
- You have completed at least 2 cycles of standard chemotherapy without achieving complete remission, or you are newly diagnosed and willing to complete first-line chemotherapy
- You have a good overall health status (ECOG score 0–2) and are expected to live at least 3 more months
- Your organ function (liver, kidney, heart, blood counts) meets safe thresholds for the trial
- You are willing to use effective birth control during treatment and for 4 months after, with a negative pregnancy test if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
Hear when a new HIV Associated Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.